|
AU4314801A
(en)
|
2000-02-11 |
2001-08-20 |
Lexigen Pharm Corp |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
CA2440221C
(en)
|
2001-03-07 |
2013-02-05 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
CN100503639C
(zh)
|
2001-05-03 |
2009-06-24 |
默克专利有限公司 |
重组肿瘤特异性抗体及其应用
|
|
ATE542137T1
(de)
|
2001-12-04 |
2012-02-15 |
Merck Patent Gmbh |
Immunocytokine mit modulierter selektivität
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
CA2872136C
(en)
|
2002-07-18 |
2017-06-20 |
Merus B.V. |
Recombinant production of mixtures of antibodies
|
|
AU2004309050B2
(en)
|
2003-12-30 |
2010-10-14 |
Merck Patent Gmbh |
IL-7 fusion proteins
|
|
CA2551916C
(en)
|
2003-12-31 |
2014-04-29 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
CA2603408C
(en)
|
2005-03-31 |
2018-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
EP1999154B1
(en)
|
2006-03-24 |
2012-10-24 |
Merck Patent GmbH |
Engineered heterodimeric protein domains
|
|
CN105177091A
(zh)
|
2006-03-31 |
2015-12-23 |
中外制药株式会社 |
用于纯化双特异性抗体的抗体修饰方法
|
|
KR101477824B1
(ko)
|
2006-09-29 |
2015-01-02 |
온코메드 파마슈티칼스, 인크. |
암의 진단 및 치료를 위한 조성물 및 방법
|
|
WO2008119353A1
(en)
|
2007-03-29 |
2008-10-09 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
AU2015202560B2
(en)
*
|
2008-01-07 |
2017-06-15 |
Amgen Inc. |
Method for Making Antibody Fc-Heterodimeric Molecules Using Electrostatic Steering Effects
|
|
DK2235064T3
(en)
*
|
2008-01-07 |
2016-01-11 |
Amgen Inc |
A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
|
|
BRPI0910484A2
(pt)
*
|
2008-04-25 |
2018-03-27 |
Merck Patent Gmbh |
esqueletos artificiais de proteína
|
|
NZ588554A
(en)
|
2008-04-29 |
2013-03-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2726087A1
(en)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
|
MX2011010159A
(es)
|
2009-04-02 |
2011-10-17 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
|
|
MX2011010168A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos, trivalentes.
|
|
EA201171259A1
(ru)
|
2009-04-22 |
2012-05-30 |
Мерк Патент Гмбх |
Антительные гибридные белки с модифицированными сайтами связывания fcrn
|
|
JP2012525149A
(ja)
*
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
JP2012532608A
(ja)
|
2009-07-08 |
2012-12-20 |
アムジェン インコーポレイテッド |
ＣＨ３ドメイン界面操作を通じた、安定でそして凝集しない抗体Ｆｃ分子の設計
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
MX2012003396A
(es)
|
2009-09-16 |
2012-04-10 |
Genentech Inc |
Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
|
|
WO2011047383A1
(en)
|
2009-10-16 |
2011-04-21 |
Oncomed Pharmaceuticals, Inc. |
Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
|
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
|
BR112012026766B1
(pt)
|
2010-04-20 |
2021-11-03 |
Genmab A/S |
Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP2598530A2
(en)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
AU2011285852B2
(en)
|
2010-08-03 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2609111B1
(en)
|
2010-08-24 |
2017-11-01 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising a disulfide stabilized-fv fragment
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
ES2758994T3
(es)
*
|
2010-11-05 |
2020-05-07 |
Zymeworks Inc |
Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
|
|
WO2012064792A2
(en)
*
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
|
AU2011337697B2
(en)
|
2010-11-30 |
2016-10-27 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
JP5768147B2
(ja)
|
2011-02-28 |
2015-08-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
一価抗原結合タンパク質
|
|
MX341921B
(es)
|
2011-02-28 |
2016-09-07 |
Hoffmann La Roche |
Proteinas de union a antigeno.
|
|
MX358752B
(es)
|
2011-03-25 |
2018-08-31 |
Glenmark Pharmaceuticals Sa |
Inmunoglobulinas heterodiméricas.
|
|
HRP20161531T1
(hr)
|
2011-04-13 |
2016-12-30 |
Bristol-Myers Squibb Company |
Fc fuzijski proteini koji sadrže nove linkere ili aranžmane
|
|
EP2699260B1
(en)
|
2011-04-20 |
2024-11-20 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
JP2014514314A
(ja)
|
2011-04-20 |
2014-06-19 |
ゲンマブ エー／エス |
Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
|
|
CN107903325B
(zh)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
LT2758073T
(lt)
|
2011-09-23 |
2019-01-10 |
Oncomed Pharmaceuticals, Inc. |
Vegf/dll4 surišantys agentai ir jų panaudojimas
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
ES2739808T3
(es)
|
2011-10-27 |
2020-02-04 |
Genmab As |
Producción de proteínas heterodiméricas
|
|
MX359775B
(es)
|
2011-10-31 |
2018-10-10 |
Chugai Pharmaceutical Co Ltd |
Molecula enlazada al antigeno que tiene conjugacion regulada entre cadena ligera y cadena pesada.
|
|
HUE056462T2
(hu)
|
2011-11-04 |
2022-02-28 |
Zymeworks Inc |
Stabil heterodimer antestest tervezés mutációkkal az FC domainben
|
|
JP2014533249A
(ja)
|
2011-11-07 |
2014-12-11 |
メディミューン，エルエルシー |
多重特異性を持つ多価結合タンパク質およびその使用
|
|
SI2794905T1
(sl)
|
2011-12-20 |
2020-08-31 |
Medimmune, Llc |
Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
|
|
KR20140127854A
(ko)
|
2012-02-10 |
2014-11-04 |
제넨테크, 인크. |
단일-쇄 항체 및 다른 이종다량체
|
|
KR102269650B1
(ko)
|
2012-04-20 |
2021-06-28 |
메뤼스 엔.페. |
Ig-유사 분자의 제조방법 및 제조수단
|
|
US9090694B2
(en)
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
KR20150023889A
(ko)
|
2012-06-27 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
|
|
EP2867254B1
(en)
|
2012-06-27 |
2017-10-25 |
F. Hoffmann-La Roche AG |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
|
SG11201408646VA
(en)
|
2012-07-06 |
2015-01-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
AU2013322710A1
(en)
|
2012-09-25 |
2015-04-16 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
US10358492B2
(en)
|
2012-09-27 |
2019-07-23 |
Merus N.V. |
Bispecific IgG antibodies as T cell engagers
|
|
JP6581505B2
(ja)
|
2012-10-03 |
2019-09-25 |
ザイムワークス，インコーポレイテッド |
重鎖および軽鎖ポリペプチドの対を定量化する方法
|
|
WO2014054804A1
(ja)
|
2012-10-05 |
2014-04-10 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
|
MX2015003616A
(es)
|
2012-10-08 |
2015-06-05 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
|
|
EP2912058A1
(en)
|
2012-10-23 |
2015-09-02 |
The Board of Regents of The University of Texas System |
Antibodies with engineered igg fc domains
|
|
US20140227252A1
(en)
|
2012-10-31 |
2014-08-14 |
Oncomed Pharmaceuticals , Inc. |
Methods and Monitoring of Treatment with a DLL4 Antagonist
|
|
CA2892059C
(en)
*
|
2012-11-21 |
2023-02-14 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
CN120173124A
(zh)
|
2012-11-28 |
2025-06-20 |
酵活英属哥伦比亚有限公司 |
工程化免疫球蛋白重链-轻链对及其用途
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
BR112015016561B1
(pt)
|
2013-01-10 |
2023-01-10 |
Genmab B.V. |
Método para aumentar a citotoxicidade dependente de complemento
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
WO2014110601A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
EP2956467B1
(en)
|
2013-02-12 |
2017-09-27 |
Bristol-Myers Squibb Company |
High ph protein refolding methods
|
|
ES2813501T3
(es)
|
2013-02-12 |
2021-03-24 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas basados en filtración de flujo tangencial
|
|
CN104936986B
(zh)
|
2013-02-26 |
2019-08-09 |
罗切格利卡特公司 |
双特异性t细胞活化性抗原结合分子
|
|
MX2015010350A
(es)
|
2013-02-26 |
2015-10-29 |
Roche Glycart Ag |
Moleculas de union a antigeno biespecificas que activan la celula t.
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
HK1220474A1
(zh)
|
2013-03-15 |
2017-05-05 |
Janssen Biotech, Inc. |
干扰素α和ω抗体拮抗剂
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
CA2906927C
(en)
|
2013-03-15 |
2021-07-13 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
KR20160006168A
(ko)
|
2013-03-18 |
2016-01-18 |
바이오서오엑스 프로덕스 비.브이. |
인간화 항-cd134(ox40) 항체 및 이의 용도
|
|
TWI653243B
(zh)
|
2013-04-29 |
2019-03-11 |
赫孚孟拉羅股份公司 |
遏止ＦｃＲｎ結合之抗ＩＧＦ－１Ｒ抗體及其治療血管性眼疾之用途
|
|
CA2904806C
(en)
|
2013-04-29 |
2021-11-23 |
F. Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
|
CN105164157B
(zh)
|
2013-04-29 |
2024-05-28 |
豪夫迈·罗氏有限公司 |
Fc-受体结合的修饰的非对称抗体及使用方法
|
|
EP3693385A1
(en)
|
2013-07-05 |
2020-08-12 |
Genmab A/S |
Humanized or chimeric cd3 antibodies
|
|
CA2925256C
(en)
|
2013-09-27 |
2023-08-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
|
WO2015052230A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
|
JP6556742B2
(ja)
|
2013-11-06 |
2019-08-07 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｃｌ１７抗体
|
|
WO2015077891A1
(en)
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
|
JP6449295B2
(ja)
|
2013-12-17 |
2019-01-09 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ３抗体および使用方法
|
|
BR112016013562A2
(pt)
|
2013-12-20 |
2017-10-03 |
Hoffmann La Roche |
Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
|
|
MX373097B
(es)
|
2014-01-03 |
2020-04-27 |
Hoffmann La Roche |
Anticuerpos biespecíficos anti-hapteno/anti-receptor de barrera hematoencefálica, complejos de los mismos y su uso como transportadores a través de la barrera hematoencefálica.
|
|
CN111057147B
(zh)
|
2014-01-06 |
2023-11-10 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
|
CN105899534B
(zh)
|
2014-01-15 |
2020-01-07 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
EP3110846B1
(en)
|
2014-02-28 |
2020-08-19 |
Merus N.V. |
Antibodies that bind egfr and erbb3
|
|
EP3110849B9
(en)
|
2014-02-28 |
2021-04-07 |
Merus N.V. |
Antibody that binds erbb-2 and erbb-3
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
KR20220126813A
(ko)
|
2014-03-14 |
2022-09-16 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
PL3122781T3
(pl)
|
2014-03-28 |
2020-06-15 |
Xencor, Inc. |
Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
|
|
SG10202107077QA
(en)
|
2014-04-02 |
2021-07-29 |
Hoffmann La Roche |
Method for detecting multispecific antibody light chain mispairing
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
SG11201607434WA
(en)
|
2014-04-07 |
2016-10-28 |
Chugai Pharmaceutical Co Ltd |
Immunoactivating antigen-binding molecule
|
|
KR20170017916A
(ko)
|
2014-05-13 |
2017-02-15 |
추가이 세이야쿠 가부시키가이샤 |
면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
|
|
CA2946503C
(en)
|
2014-05-28 |
2022-11-22 |
Zymeworks Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
JP6654581B2
(ja)
|
2014-06-26 |
2020-02-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗ｂｒｄｕ抗体および使用方法
|
|
KR20170010863A
(ko)
|
2014-07-01 |
2017-02-01 |
화이자 인코포레이티드 |
이중특이성 이종이량체성 디아바디 및 이의 용도
|
|
HRP20200283T1
(hr)
|
2014-07-11 |
2020-05-29 |
Genmab A/S |
Protutijela koja se vežu na axl
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
RS65573B1
(sr)
|
2014-08-04 |
2024-06-28 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
|
DK3183268T3
(da)
|
2014-08-19 |
2020-05-11 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
|
|
SG11201701867SA
(en)
|
2014-09-09 |
2017-04-27 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
JP6886398B2
(ja)
|
2014-09-12 |
2021-06-16 |
ジェネンテック， インコーポレイテッド |
Ａｎｔｉ−ｃｌｌ−１抗体及び免疫複合体
|
|
MX2017003645A
(es)
|
2014-09-17 |
2017-05-30 |
Novartis Ag |
Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
AU2015329965A1
(en)
|
2014-10-09 |
2017-04-27 |
Engmab Sàrl |
Bispecific antibodies against CD3epsilon and ROR1
|
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
CA2966042A1
(en)
|
2014-10-31 |
2016-05-06 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
KR20170076697A
(ko)
|
2014-11-06 |
2017-07-04 |
에프. 호프만-라 로슈 아게 |
개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체
|
|
RU2714116C2
(ru)
|
2014-11-06 |
2020-02-11 |
Ф. Хоффманн-Ля Рош Аг |
ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМ СВЯЗЫВАНИЕМ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
|
AU2015348595B2
(en)
|
2014-11-20 |
2021-06-10 |
F. Hoffmann-La Roche Ag |
T cell activating bispecific antigen binding molecules against FOLR1 and CD3
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
HUE049650T2
(hu)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Közös könnyûláncok és alkalmazási eljárások
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
HRP20211273T1
(hr)
|
2014-11-26 |
2021-11-12 |
Xencor, Inc. |
Heterodimerna protutijela koja vežu cd3 i cd20
|
|
TN2017000222A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
|
PE20171094A1
(es)
|
2014-12-04 |
2017-08-07 |
Janssen Biotech Inc |
Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
|
|
US10982008B2
(en)
|
2014-12-05 |
2021-04-20 |
Merck Patent Gmbh |
Domain-exchanged antibody
|
|
WO2016097300A1
(en)
|
2014-12-19 |
2016-06-23 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
AU2016219511B2
(en)
|
2015-02-09 |
2020-11-12 |
Research Development Foundation |
Engineered immunoglobulin Fc polypeptides displaying improved complement activation
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
IL254817B2
(en)
|
2015-04-08 |
2023-12-01 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CA2986594C
(en)
|
2015-05-20 |
2025-06-10 |
Tufts Medical Center Inc |
Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
|
|
CN104833797B
(zh)
*
|
2015-06-04 |
2017-02-01 |
武汉友芝友生物制药有限公司 |
检测双特异性抗体msbody的elisa方法及应用
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
|
FI3310814T3
(fi)
|
2015-06-16 |
2023-09-21 |
Hoffmann La Roche |
HUMANISOITUJA JA AFFINITEETTIKYPSIÄ FcRH5-VASTA-AINEITA JA KÄYTTÖMENETELMIÄ
|
|
UA125115C2
(uk)
|
2015-06-22 |
2022-01-12 |
Янссен Байотек, Інк. |
Спосіб лікування суб'єкта, який має множинну мієлому (мм)
|
|
US9862763B2
(en)
|
2015-06-24 |
2018-01-09 |
Hoffmann-La Roche Inc. |
Humanized anti-tau(pS422) antibodies and methods of use
|
|
BR112017027990A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Biotech, Inc. |
modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38
|
|
WO2017005649A1
(en)
|
2015-07-09 |
2017-01-12 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
|
PL3115376T3
(pl)
|
2015-07-10 |
2019-01-31 |
Merus N.V. |
Ludzkie przeciwciało wiążące cd3
|
|
EA201890272A1
(ru)
|
2015-07-10 |
2018-08-31 |
Генмаб А/С |
Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
|
|
KR20250048113A
(ko)
|
2015-07-15 |
2025-04-07 |
젠맵 에이/에스 |
인간화 또는 키메라 cd3 항체
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
MA42542B1
(fr)
|
2015-07-30 |
2021-09-30 |
Macrogenics Inc |
Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
|
|
EP3331563B1
(en)
|
2015-08-05 |
2023-04-19 |
Janssen Biotech, Inc. |
Anti-cd154 antibodies and methods of using them
|
|
WO2017053705A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
|
US10544229B2
(en)
|
2015-09-30 |
2020-01-28 |
Janssen Biotech, Inc. |
Agonistic antibodies specifically binding CD40 and methods of use
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3913000A1
(en)
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
JP2018536389A
(ja)
|
2015-10-02 |
2018-12-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
メソテリンとｃｄ３に結合する二重特異性細胞活性化抗原結合分子
|
|
EP3356821B1
(en)
|
2015-10-02 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
AR106199A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas activadoras de células t
|
|
CR20180162A
(es)
|
2015-10-02 |
2018-05-25 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
JP6622392B2
(ja)
|
2015-10-02 |
2019-12-18 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ１とｔｉｍ３に特異的な二重特異性抗体
|
|
KR20250079249A
(ko)
|
2015-10-08 |
2025-06-04 |
마크로제닉스, 인크. |
암 치료를 위한 조합 치료법
|
|
PL3359576T3
(pl)
|
2015-10-08 |
2025-04-14 |
Zymeworks Bc Inc. |
Konstrukty polipeptydowe wiążące antygen zawierające łańcuchy lekkie kappa i lambda oraz ich zastosowania
|
|
CA3002957A1
(en)
|
2015-10-23 |
2017-04-27 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Binding molecules that inhibit cancer growth
|
|
EP4015533A1
(en)
|
2015-10-29 |
2022-06-22 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
|
JP2019500011A
(ja)
*
|
2015-11-03 |
2019-01-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
|
|
HRP20220680T1
(hr)
|
2015-11-03 |
2022-07-08 |
Janssen Biotech, Inc. |
Potkožne formulacije protutijela anti-cd38 i njihove uporabe
|
|
EA201891093A1
(ru)
|
2015-11-03 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела, специфически связывающие pd-1, и их применение
|
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
MX2018006333A
(es)
|
2015-12-01 |
2018-08-01 |
Genmab Bv |
Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
|
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
JP7325186B2
(ja)
|
2015-12-09 |
2023-08-14 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体
|
|
BR112018011781A2
(en)
|
2015-12-14 |
2018-12-04 |
Macrogenics, Inc. |
bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
CA3007421A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
EP3390453A2
(en)
|
2015-12-17 |
2018-10-24 |
Janssen Biotech, Inc. |
Antibodies specifically binding hla-dr and their uses
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
|
EP3405492B1
(en)
|
2016-01-21 |
2020-10-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
WO2017142928A1
(en)
|
2016-02-17 |
2017-08-24 |
Macrogenics, Inc. |
Ror1-binding molecules, and methods of use thereof
|
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
AU2017233658B2
(en)
|
2016-03-14 |
2023-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
|
AU2017238172B2
(en)
|
2016-03-21 |
2024-06-27 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
PL3433280T3
(pl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy
|
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
SG11201809041TA
(en)
|
2016-04-15 |
2018-11-29 |
Novartis Ag |
Compositions and methods for selective protein expression
|
|
EP3442574A4
(en)
|
2016-04-15 |
2019-12-11 |
MacroGenics, Inc. |
Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
|
|
JP7134868B2
(ja)
|
2016-04-20 |
2022-09-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
発現強化座位の使用に基づく抗体を作製するための組成物および方法
|
|
SG11201807885PA
(en)
|
2016-04-20 |
2018-10-30 |
Regeneron Pharma |
Compositions and methods for making antibodies based on use of expression-enhancing loci
|
|
MA56474A
(fr)
|
2016-05-02 |
2022-05-11 |
Hoffmann La Roche |
Contorsbody - liant de cible à chaîne unique
|
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
AU2018276419A1
(en)
|
2016-06-02 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
EP3464375A2
(en)
|
2016-06-02 |
2019-04-10 |
Novartis AG |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
HRP20241447T1
(hr)
|
2016-06-14 |
2025-01-03 |
Xencor, Inc. |
Bispecifična inhibitor antitijela kontrolnih točaka
|
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
WO2018005954A2
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
|
WO2018007314A1
(en)
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
|
BR112019000512A2
(pt)
|
2016-07-14 |
2019-04-24 |
Genmab A/S |
anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
|
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
KR20250061769A
(ko)
|
2016-07-28 |
2025-05-08 |
노파르티스 아게 |
키메라 항원 수용체 및 pd-1 억제제의 조합 요법
|
|
JP2019527696A
(ja)
|
2016-08-01 |
2019-10-03 |
ノバルティス アーゲー |
プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
|
|
KR102050463B1
(ko)
|
2016-08-10 |
2019-11-29 |
아주대학교산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
|
|
WO2018031258A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
WO2018031400A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
RS61932B1
(sr)
|
2016-09-14 |
2021-07-30 |
Merck Patent Gmbh |
Antitela na c-met i njihovi konjugati leka sa antitelom za efikasnu inhibiciju tumora
|
|
US10738120B2
(en)
|
2016-09-20 |
2020-08-11 |
Merck Patent Gmbh |
Diagnostic anti-PD-L1 antibody and use thereof
|
|
JP6785372B2
(ja)
|
2016-09-30 |
2020-11-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
|
|
WO2018060301A1
(en)
|
2016-09-30 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against cd3
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
KR102562519B1
(ko)
|
2016-10-14 |
2023-08-02 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
|
|
JP7277363B2
(ja)
|
2016-11-01 |
2023-05-18 |
ジェンマブ ビー．ブイ． |
ポリペプチド変異体およびその使用
|
|
JP2020503260A
(ja)
|
2016-11-15 |
2020-01-30 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
WO2018095932A1
(en)
|
2016-11-22 |
2018-05-31 |
Merck Patent Gmbh |
Monoclonal antibody directed to fgfr1
|
|
MX2019007404A
(es)
|
2016-12-23 |
2019-09-27 |
Macrogenics Inc |
Moleculas de union a adam9 y metodos de uso de las mismas.
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
EP3577137A1
(en)
|
2017-02-02 |
2019-12-11 |
Merck Patent GmbH |
Preferred pairing of antibody domains
|
|
US12173076B2
(en)
|
2017-02-10 |
2024-12-24 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
EP3586872A4
(en)
|
2017-02-24 |
2020-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
PHARMACEUTICAL COMPOSITION, ANTIGEN BINDING MOLECULES, METHOD OF TREATMENT AND METHOD OF SCREENING
|
|
WO2018158719A1
(en)
|
2017-03-02 |
2018-09-07 |
Novartis Ag |
Engineered heterodimeric proteins
|
|
EP4527854A3
(en)
|
2017-03-09 |
2025-06-25 |
Genmab A/S |
Antibodies against pd-l1
|
|
CA3052357A1
(en)
|
2017-03-10 |
2018-09-13 |
F. Hoffmann-La Roche Ag |
Method for producing multispecific antibodies
|
|
WO2018170288A1
(en)
|
2017-03-15 |
2018-09-20 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
AU2018242227B2
(en)
|
2017-03-31 |
2025-04-10 |
Genmab Holding B.V. |
Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
|
|
BR112019020508A2
(pt)
|
2017-03-31 |
2020-08-04 |
Merus N.V. |
anticorpos biespecíficos de ligação a erbb-2 e erbb3 para utilização no tratamento de células que possuem um gene de fusão nrg1
|
|
EP3606963B1
(en)
|
2017-04-03 |
2023-08-30 |
F. Hoffmann-La Roche AG |
Antibodies binding to steap-1
|
|
EP3606960A1
(en)
|
2017-04-03 |
2020-02-12 |
Oncologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
CN110392692B
(zh)
|
2017-04-03 |
2023-07-21 |
豪夫迈·罗氏有限公司 |
抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
|
|
KR102346336B1
(ko)
|
2017-04-05 |
2022-01-04 |
에프. 호프만-라 로슈 아게 |
Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
|
|
MX2019012187A
(es)
|
2017-04-13 |
2019-11-25 |
Hoffmann La Roche |
Un inmunoconjugado de interleuquina-2, un agonista de cd40 y opcionalmente un antagonista de union al eje pd-1 para uso en metodos para tratar cancer.
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
KR102744809B1
(ko)
|
2017-05-17 |
2024-12-23 |
메뤼스 엔.페. |
유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합
|
|
CA3064435A1
(en)
|
2017-05-24 |
2018-11-29 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
WO2018224609A1
(en)
|
2017-06-07 |
2018-12-13 |
Genmab B.V. |
Therapeutic antibodies based on mutated igg hexamers
|
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
|
MX2019015738A
(es)
|
2017-06-27 |
2020-02-20 |
Novartis Ag |
Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
|
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
SG10201913144TA
(en)
|
2017-07-11 |
2020-03-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
CN111163798A
(zh)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
用于抗lag-3抗体的给药方案及其用途
|
|
KR102758346B1
(ko)
|
2017-08-04 |
2025-01-24 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
KR20200042485A
(ko)
|
2017-08-09 |
2020-04-23 |
메뤼스 엔.페. |
EGFR 및 cMET에 결합하는 항체
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
MX2020002070A
(es)
|
2017-08-22 |
2020-03-24 |
Sanabio Llc |
Receptores solubles de interferon y usos de los mismos.
|
|
IL272807B2
(en)
|
2017-08-30 |
2024-07-01 |
Ares Trading Sa |
Method for purifying proteins
|
|
CN111132997A
(zh)
|
2017-09-21 |
2020-05-08 |
默克专利有限公司 |
包含fgf-18部分的融合蛋白
|
|
SG11202002581WA
(en)
|
2017-09-21 |
2020-04-29 |
Umc Utrecht Holding Bv |
Anti-gd2 antibody for the treatment of neuroblastoma
|
|
CA3078157A1
(en)
|
2017-10-20 |
2019-04-25 |
F.Hoffmann-La Roche Ag |
Method for generating multispecific antibodies from monospecific antibodies
|
|
CA3078676A1
(en)
|
2017-10-30 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
WO2019086499A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Novel tnf family ligand trimer-containing antigen binding molecules
|
|
CN111182944B
(zh)
|
2017-11-01 |
2022-11-22 |
豪夫迈·罗氏有限公司 |
双特异性2+1 Contorsbody
|
|
EP3704150A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
The compbody - a multivalent target binder
|
|
MX2020004196A
(es)
|
2017-11-01 |
2020-11-09 |
Hoffmann La Roche |
Trifab-contorsbody.
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
BR112020011810A2
(pt)
|
2017-12-12 |
2020-11-17 |
Macrogenics, Inc. |
molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
|
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
PE20201149A1
(es)
|
2017-12-21 |
2020-10-26 |
Hoffmann La Roche |
Anticuerpos de union a hla-a2/wt1
|
|
EP3728327A1
(en)
|
2017-12-22 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
BR112020013325A2
(pt)
|
2018-01-12 |
2020-12-01 |
Genzyme Corporation |
métodos para quantificação de polipeptídeos
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
MA51666A
(fr)
|
2018-01-24 |
2020-12-02 |
Genmab Bv |
Variants polypeptidiques et leurs utilisations
|
|
AU2019215031B2
(en)
|
2018-01-31 |
2025-10-09 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
CN119909169A
(zh)
|
2018-02-06 |
2025-05-02 |
豪夫迈·罗氏有限公司 |
眼科疾病的治疗
|
|
US11866498B2
(en)
|
2018-02-08 |
2024-01-09 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
WO2019160007A1
(ja)
|
2018-02-14 |
2019-08-22 |
中外製薬株式会社 |
抗原結合分子および組合せ
|
|
CA3089877A1
(en)
|
2018-02-15 |
2019-08-22 |
Macrogenics, Inc. |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
|
BR112020018490A2
(pt)
|
2018-03-12 |
2020-12-29 |
Genmab A/S |
Anticorpo, imunoconjugado ou conjugado de anticorpo-fármaco, construção de ácido nucléico, vetor de expressão, célula, composição, composição farmacêutica, anticorpo, método, método para produzir um anticorpo, kit de partes, e, anticorpo anti-idiotípico
|
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
SG11202010159RA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
US11505595B2
(en)
|
2018-04-18 |
2022-11-22 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
AU2019264217A1
(en)
|
2018-05-03 |
2020-12-17 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
AU2019270623B2
(en)
|
2018-05-16 |
2023-09-07 |
Janssen Biotech, Inc. |
BCMA/CD3 and GPRDC5D/CD3 bispecific antibodies for use in cancer therapy
|
|
WO2019219891A1
(en)
|
2018-05-18 |
2019-11-21 |
Daiichi Sankyo Co., Ltd. |
Anti-muc1 antibody-drug conjugate
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
EP3797120A1
(en)
|
2018-05-21 |
2021-03-31 |
Compass Therapeutics LLC |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
MA52772A
(fr)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech Inc |
Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
|
|
EA202092839A1
(ru)
|
2018-05-24 |
2021-02-12 |
Янссен Байотек, Инк. |
Агенты, связывающиеся с psma, и виды их применения
|
|
US11603405B2
(en)
|
2018-05-24 |
2023-03-14 |
Janssen Biotech, Inc. |
Anti-CD3 antibodies and uses thereof
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
WO2019241426A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
EP3810194A1
(en)
|
2018-06-22 |
2021-04-28 |
Genmab Holding B.V. |
Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
|
|
JP7554742B2
(ja)
|
2018-07-03 |
2024-09-20 |
マレンゴ・セラピューティクス，インコーポレーテッド |
抗ｔｃｒ抗体分子およびその使用
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
KR20210031932A
(ko)
|
2018-07-13 |
2021-03-23 |
젠맵 에이/에스 |
Cd38 항체의 변이체 및 그의 용도
|
|
EP3820890A1
(en)
|
2018-07-13 |
2021-05-19 |
Genmab A/S |
Trogocytosis-mediated therapy using cd38 antibodies
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
US20210188957A1
(en)
|
2018-08-29 |
2021-06-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-molecule
|
|
WO2020043849A1
(en)
|
2018-08-29 |
2020-03-05 |
Merck Biodevelopment S.A.S. |
New purification method
|
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
WO2020048525A1
(en)
|
2018-09-07 |
2020-03-12 |
Generon (Shanghai) Corporation Ltd. |
Bispecific antigen binding proteins and uses thereof
|
|
US11667721B2
(en)
|
2018-09-24 |
2023-06-06 |
Medical College Of Wisconsin, Inc. |
CD30 bispecific antibodies and method of immunotherapy of CD30+ malignancies
|
|
MA53822A
(fr)
|
2018-10-03 |
2021-08-11 |
Xencor Inc |
Protéines de fusion fc hétérodimères d'il -12
|
|
MX2021003756A
(es)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
|
|
MA53862A
(fr)
|
2018-10-12 |
2022-01-19 |
Xencor Inc |
Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
|
|
CA3117212A1
(en)
|
2018-10-23 |
2020-04-30 |
Dragonfly Therapeutics, Inc. |
Heterodimeric fc-fused proteins
|
|
SG11202103064YA
(en)
|
2018-10-29 |
2021-05-28 |
Hoffmann La Roche |
Antibody formulation
|
|
JP2022505866A
(ja)
|
2018-11-02 |
2022-01-14 |
ユニバーシティ オブ ワシントン |
直交タンパク質ヘテロ二量体
|
|
BR112021008774A2
(pt)
|
2018-11-06 |
2021-11-30 |
BioNTech SE |
Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica
|
|
AU2019379576A1
(en)
|
2018-11-13 |
2021-06-03 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
WO2020115115A1
(en)
|
2018-12-05 |
2020-06-11 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
|
TWI874341B
(zh)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
產生異二聚體抗體之方法
|
|
GB201820687D0
(en)
|
2018-12-19 |
2019-01-30 |
Kymab Ltd |
Antagonists
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
US11618776B2
(en)
|
2018-12-20 |
2023-04-04 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
|
|
WO2020128894A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
|
|
LT3723858T
(lt)
|
2018-12-21 |
2022-02-10 |
Kymab Limited |
Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę
|
|
CN118271445A
(zh)
|
2018-12-21 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
与cd3结合的抗体
|
|
WO2020136564A1
(en)
|
2018-12-24 |
2020-07-02 |
Sanofi |
Pseudofab-based multispecific binding proteins
|
|
US11965030B2
(en)
|
2018-12-24 |
2024-04-23 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
|
EP3902560A1
(en)
|
2018-12-28 |
2021-11-03 |
F. Hoffmann-La Roche AG |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
BR112021013193A2
(pt)
*
|
2019-01-07 |
2021-09-28 |
Shattuck Labs, Inc. |
Proteínas heterodiméricas para modulação de células t gama delta
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
JOP20210194A1
(ar)
|
2019-01-18 |
2023-01-30 |
Janssen Biotech Inc |
مستقبلات المستضدات الخيمرية لـ gprc5d وخلايا تعبر عنها
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
EA202192019A1
(ru)
|
2019-02-15 |
2021-11-02 |
Новартис Аг |
Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
|
|
JP7488826B2
(ja)
|
2019-02-15 |
2024-05-22 |
ノバルティス アーゲー |
置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
SG11202109056TA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
AU2020226904B2
(en)
|
2019-02-21 |
2025-05-01 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
CN114127111B
(zh)
|
2019-02-21 |
2024-09-10 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
EP3927744A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
CN114127112A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
BR112021016149A2
(pt)
|
2019-02-26 |
2021-10-13 |
Janssen Biotech, Inc. |
Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
|
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
KR20220004979A
(ko)
|
2019-03-27 |
2022-01-12 |
유엠씨 우트레크트 홀딩 비.브이. |
조작된 iga 항체 및 사용 방법
|
|
CN113646622B
(zh)
|
2019-03-29 |
2024-11-12 |
豪夫迈·罗氏有限公司 |
用于多价分子的功能分析的基于spr的结合测定
|
|
WO2020200944A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Method for generating avid-binding multispecific antibodies
|
|
KR20220029546A
(ko)
|
2019-03-29 |
2022-03-08 |
아타르가, 엘엘씨 |
항 fgf23 항체
|
|
CA3136888A1
(en)
|
2019-04-19 |
2020-10-22 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti- psma/cd3 antibody
|
|
KR20220005031A
(ko)
|
2019-04-25 |
2022-01-12 |
에프. 호프만-라 로슈 아게 |
폴리펩티드 사슬 교환에 의한 항체-유래된 폴리펩티드의 산출
|
|
AU2020262309A1
(en)
|
2019-04-25 |
2021-10-14 |
F. Hoffmann-La Roche Ag |
Therapeutic multispecific polypeptides activated by polypeptide chain exchange
|
|
CN113767114A
(zh)
|
2019-04-25 |
2021-12-07 |
豪夫迈·罗氏有限公司 |
半衰期延长的可活化治疗性多特异性多肽
|
|
US11667712B2
(en)
|
2019-05-08 |
2023-06-06 |
Janssen Biotech, Inc. |
Materials and methods for modulating t cell mediated immunity
|
|
EP3966241A1
(en)
|
2019-05-09 |
2022-03-16 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
CN113811770B
(zh)
|
2019-05-13 |
2024-06-28 |
豪夫迈·罗氏有限公司 |
抑制干扰的药代动力学免疫测定
|
|
JOP20210304A1
(ar)
|
2019-05-14 |
2023-01-30 |
Janssen Biotech Inc |
علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
|
|
CN114679909A
(zh)
|
2019-05-20 |
2022-06-28 |
潘迪恩运营公司 |
MAdCAM靶向的免疫耐受
|
|
AU2020285636A1
(en)
*
|
2019-05-24 |
2021-11-04 |
Proviva Therapeutics (Hong Kong) Limited |
IL-2 compositions and methods of use thereof
|
|
BR112021025425A2
(pt)
|
2019-06-19 |
2022-02-01 |
Hoffmann La Roche |
Método para produzir uma célula de mamífero recombinante e uso de mrna de recombinase cre
|
|
EP3990646B1
(en)
|
2019-06-26 |
2025-03-05 |
F. Hoffmann-La Roche AG |
Mammalian cell lines with sirt-1 gene knockout
|
|
EP3994169A1
(en)
|
2019-07-02 |
2022-05-11 |
F. Hoffmann-La Roche AG |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
US12077585B2
(en)
|
2019-07-26 |
2024-09-03 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
|
WO2021018925A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
EP4003526A2
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
BR112022002540A2
(pt)
|
2019-08-15 |
2022-06-14 |
Janssen Biotech Inc |
Materiais e métodos para fragmentos variáveis de cadeia única aprimorados
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
KR20220103947A
(ko)
|
2019-10-21 |
2022-07-25 |
노파르티스 아게 |
베네토클락스 및 tim-3 억제제를 사용한 조합 요법
|
|
CA3157665A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
|
JP2023500701A
(ja)
|
2019-11-06 |
2023-01-10 |
ジェンマブ ビー．ブイ． |
抗体変種の組み合わせおよびその使用
|
|
MX2022005983A
(es)
|
2019-11-18 |
2022-09-07 |
Janssen Biotech Inc |
Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
|
|
MX2022006391A
(es)
|
2019-11-26 |
2022-06-24 |
Novartis Ag |
Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
|
|
CN114867494B9
(zh)
|
2019-12-13 |
2024-01-12 |
基因泰克公司 |
抗ly6g6d抗体及使用方法
|
|
US11987632B2
(en)
|
2019-12-18 |
2024-05-21 |
Hoffmann-La Roche Inc. |
Antibodies binding to HLA-A2/MAGE-A4
|
|
KR20220113791A
(ko)
|
2019-12-18 |
2022-08-16 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
CN114930170A
(zh)
|
2020-01-02 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
用于测定脑中的治疗性抗体量的方法
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
US20230272105A1
(en)
|
2020-01-16 |
2023-08-31 |
Genmab A/S |
Formulations of cd38 antibodies and uses thereof
|
|
AU2021207348A1
(en)
|
2020-01-17 |
2022-08-11 |
Novartis Ag |
Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
US20210222244A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
IL295129A
(en)
|
2020-01-30 |
2022-09-01 |
Umoja Biopharma Inc |
Bispecific transduction enhancer
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
JOP20220184A1
(ar)
|
2020-02-12 |
2023-01-30 |
Janssen Biotech Inc |
علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
EP4107187A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
|
|
EP4110377A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
JOP20220220A1
(ar)
|
2020-03-13 |
2023-01-30 |
Janssen Biotech Inc |
مواد وطرق لربط لكتين شبيه بالجوبيولين المناعي بحمض سياليك
|
|
KR20220154757A
(ko)
|
2020-03-18 |
2022-11-22 |
젠맵 에이/에스 |
B7h4에 결합하는 항체
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
KR20220156912A
(ko)
|
2020-03-25 |
2022-11-28 |
일라이 릴리 앤드 캄파니 |
다중특이적 결합 단백질 및 그의 개발 방법
|
|
EP4126942A1
(en)
*
|
2020-03-30 |
2023-02-08 |
Sanofi |
Split ch2 domains
|
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
BR112022020629A2
(pt)
|
2020-04-15 |
2022-11-29 |
Hoffmann La Roche |
Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
|
|
CA3180321A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
MX2022013465A
(es)
|
2020-04-30 |
2023-01-11 |
Bristol Myers Squibb Co |
Metodos para tratar eventos adversos relacionados con citocinas.
|
|
MX2022013797A
(es)
|
2020-05-08 |
2022-11-30 |
Genmab As |
Anticuerpos biespecificos contra cd3 y cd20.
|
|
BR112022022614A2
(pt)
|
2020-05-11 |
2023-02-07 |
Hoffmann La Roche |
Métodos para estimular uma resposta imune, melhorar uma imunoterapia, tratar uma doença, reduzir crescimento tumoral, produzir um imunoconjugado e produzir uma composição, método de vacinação, imunoconjugados, composição, usos e kits
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
PE20230389A1
(es)
|
2020-05-27 |
2023-03-06 |
Janssen Biotech Inc |
Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
|
|
JP2023528488A
(ja)
|
2020-06-03 |
2023-07-04 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｅｇｆｒおよびｍｕｃ１を標的とする二重特異性抗体－薬物抱合体およびその使用
|
|
CR20220629A
(es)
|
2020-06-19 |
2023-02-17 |
Hoffmann La Roche |
Moléculas de unión al dominio fc de activación inmunitaria
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
IL296089A
(en)
|
2020-06-19 |
2022-11-01 |
Hoffmann La Roche |
Antibodies binding to cd3
|
|
WO2021255143A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and folr1
|
|
EP4168447A1
(en)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3 and cd19
|
|
IL298262A
(en)
|
2020-06-23 |
2023-01-01 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US12295997B2
(en)
|
2020-07-06 |
2025-05-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
MX2023000547A
(es)
|
2020-07-16 |
2023-02-13 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
|
|
WO2022018294A1
(en)
|
2020-07-23 |
2022-01-27 |
Genmab B.V. |
A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
CN116209681A
(zh)
|
2020-07-29 |
2023-06-02 |
詹森生物科技公司 |
包含hla-g抗原结合结构域的蛋白质及其用途
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN116194477A
(zh)
|
2020-08-06 |
2023-05-30 |
生物技术欧洲股份公司 |
冠状病毒s蛋白的结合剂
|
|
MX2023001962A
(es)
|
2020-08-19 |
2023-04-26 |
Xencor Inc |
Composiciones anti-cd28.
|
|
EP4204450A4
(en)
|
2020-08-26 |
2024-11-13 |
Marengo Therapeutics, Inc. |
MULTIFUNCTIONAL CALRETICULIN-BINDING MOLECULES AND RELATED USES
|
|
EP4204458A4
(en)
|
2020-08-26 |
2024-10-09 |
Marengo Therapeutics, Inc. |
METHODS FOR DETECTION OF TRBC1 OR TRBC2
|
|
CN116917316A
(zh)
|
2020-08-26 |
2023-10-20 |
马伦戈治疗公司 |
与NKp30结合的抗体分子及其用途
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022049220A2
(en)
|
2020-09-02 |
2022-03-10 |
Genmab A/S |
Antibody therapy
|
|
EP4210747A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
IL301096A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
|
KR20230069187A
(ko)
|
2020-09-14 |
2023-05-18 |
서트로 바이오파마, 인크. |
무세포 단백질 합성 시스템을 이용한 항체의 대량 생산 방법
|
|
CA3195257A1
(en)
|
2020-09-24 |
2022-03-31 |
F. Hoffmann-La Roche Ag |
Mammalian cell lines with gene knockout
|
|
US20230365714A1
(en)
|
2020-10-02 |
2023-11-16 |
Genmab A/S |
Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
|
|
WO2022081516A1
(en)
|
2020-10-13 |
2022-04-21 |
Janssen Biotech, Inc. |
Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
|
|
TW202233672A
(zh)
|
2020-10-22 |
2022-09-01 |
美商健生生物科技公司 |
包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
|
|
WO2022087458A1
(en)
|
2020-10-23 |
2022-04-28 |
Asher Biotherapeutics, Inc. |
Fusions with cd8 antigen binding molecules for modulating immune cell function
|
|
CA3199767A1
(en)
|
2020-10-28 |
2022-05-05 |
Janssen Biotech, Inc. |
Compositions and methods for modulating delta gamma chain mediated immunity
|
|
MX2023005132A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
|
|
EP4240765A2
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Antibody fc variants
|
|
EP4245317A4
(en)
|
2020-11-10 |
2024-11-06 |
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. |
BISPECIFIC ANTIBODY FOR CLAUDIN 18A2 AND CD3 AND APPLICATION OF BISPECIFIC ANTIBODY
|
|
IL302700A
(en)
|
2020-11-13 |
2023-07-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
IL303656A
(en)
|
2020-12-17 |
2023-08-01 |
Hoffmann La Roche |
Anti-hla-g antibodies and use thereof
|
|
WO2022128716A1
(en)
|
2020-12-17 |
2022-06-23 |
Merck Patent Gmbh |
Pharmaceutical composition comprising a bispecific anti-muc1/egfr antibody-drug conjugate
|
|
JP2023553692A
(ja)
|
2020-12-18 |
2023-12-25 |
エフ． ホフマン－ラ ロシュ アーゲー |
標的治療のための前駆体タンパク質及びキット
|
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｘｂｐ１を標的とするオリゴヌクレオチド
|
|
AU2022206061A1
(en)
|
2021-01-06 |
2023-07-06 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
US20240059789A1
(en)
|
2021-01-28 |
2024-02-22 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
EP4294430A1
(en)
|
2021-02-16 |
2023-12-27 |
Janssen Biotech, Inc. |
Materials and methods for enhanced linker targeting
|
|
EP4295154A1
(en)
|
2021-02-18 |
2023-12-27 |
F. Hoffmann-La Roche AG |
Method for resolving complex, multistep antibody interactions
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
IL305700A
(en)
|
2021-03-09 |
2023-11-01 |
Janssen Biotech Inc |
Treatment of cancers lacking EFGR-activating mutations
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
KR20230156921A
(ko)
|
2021-03-12 |
2023-11-15 |
젠맵 에이/에스 |
비-활성화 항체 변이체
|
|
CA3214307A1
(en)
|
2021-03-24 |
2022-09-29 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
|
IL306103A
(en)
|
2021-03-24 |
2023-11-01 |
Janssen Biotech Inc |
The antibody targets CD22 and CD79B
|
|
US20240301031A1
(en)
|
2021-03-31 |
2024-09-12 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Truncated taci polypeptide and fusion protein and use thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
GB2623199A
(en)
|
2021-04-08 |
2024-04-10 |
Marengo Therapeutics Inc |
Multifunctional molecules binding to TCR and uses thereof
|
|
KR20230160389A
(ko)
|
2021-04-22 |
2023-11-23 |
광동 파폰 바이오파마 인크. |
이중 특이성 다기능 융합 폴리펩티드
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
WO2022228706A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
MX2023012351A
(es)
|
2021-05-07 |
2023-10-31 |
Genmab As |
Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3).
|
|
EP4339207A4
(en)
|
2021-05-12 |
2024-12-25 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
|
|
IL308417A
(en)
|
2021-05-14 |
2024-01-01 |
Genentech Inc |
Methods for the treatment of CD20-positive proliferative disorder with musuntozumab and folatuzumab and dotin
|
|
CA3219388A1
(en)
|
2021-05-14 |
2022-11-17 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
TW202309094A
(zh)
|
2021-05-18 |
2023-03-01 |
美商健生生物科技公司 |
用於識別癌症患者以進行組合治療之方法
|
|
EP4340866A4
(en)
|
2021-05-19 |
2025-05-21 |
Asher Biotherapeutics, Inc. |
Il-21 polypeptides and targeted constructs
|
|
KR20240021859A
(ko)
|
2021-06-18 |
2024-02-19 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
|
TW202315891A
(zh)
|
2021-06-21 |
2023-04-16 |
丹麥商珍美寶股份有限公司 |
結合劑給藥排程
|
|
IL309071A
(en)
|
2021-07-02 |
2024-02-01 |
Genentech Inc |
Methods and compositions for the treatment of cancer
|
|
AU2022309554A1
(en)
|
2021-07-14 |
2024-02-22 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
|
|
CN117730102A
(zh)
|
2021-07-22 |
2024-03-19 |
豪夫迈·罗氏有限公司 |
异二聚体Fc结构域抗体
|
|
JP2024527020A
(ja)
|
2021-07-27 |
2024-07-19 |
モルフォシス・アーゲー |
抗原結合分子の組合せ
|
|
CN117715936A
(zh)
|
2021-07-28 |
2024-03-15 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的方法和组合物
|
|
AU2022338208A1
(en)
|
2021-09-06 |
2024-03-21 |
Genmab A/S |
Antibodies capable of binding to cd27, variants thereof and uses thereof
|
|
TW202328193A
(zh)
|
2021-09-13 |
2023-07-16 |
美商健生生物科技公司 |
用於治療癌症的CD33 x Vδ2多特異性抗體
|
|
US20250223376A1
(en)
|
2021-09-20 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4406968A4
(en)
|
2021-09-23 |
2025-03-12 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
ANTI-KLB ANTIBODIES AND USES
|
|
EP4405392A1
(en)
|
2021-09-24 |
2024-07-31 |
Janssen Biotech, Inc. |
Proteins comprising cd20 binding domains, and uses thereof
|
|
JP2024536870A
(ja)
|
2021-09-30 |
2024-10-08 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
抗ｉｌ２３抗体融合タンパク質及び使用
|
|
MX2024003615A
(es)
|
2021-10-08 |
2024-04-09 |
Genmab As |
Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3).
|
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
PE20241627A1
(es)
|
2021-10-14 |
2024-08-07 |
Hoffmann La Roche |
Nuevos inmunoconjugados de interleucina-7
|
|
JP2024540054A
(ja)
|
2021-11-03 |
2024-10-31 |
ヤンセン バイオテツク，インコーポレーテツド |
癌を治療する方法及びｂｃｍａ×ｃｄ３二重特異性抗体の有効性を向上させる方法
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
IL312968A
(en)
|
2021-11-22 |
2024-07-01 |
Janssen Biotech Inc |
Compositions comprising enhanced multispecific binding agents for an immune response
|
|
WO2023094282A1
(en)
|
2021-11-25 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Quantification of low amounts of antibody sideproducts
|
|
US20230183360A1
(en)
|
2021-12-09 |
2023-06-15 |
Janssen Biotech, Inc. |
Use of Amivantamab to Treat Colorectal Cancer
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
|
TW202337902A
(zh)
|
2022-02-07 |
2023-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合ｐｓｍａ和ｃｄ３的抗原結合分子及其醫藥用途
|
|
TW202342057A
(zh)
|
2022-02-07 |
2023-11-01 |
美商健生生物科技公司 |
用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
|
|
MX2024009715A
(es)
|
2022-02-11 |
2024-08-19 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Inmunoconjugado y su uso del mismo.
|
|
MX2024011128A
(es)
|
2022-03-14 |
2024-09-18 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico.
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
IL315451A
(en)
|
2022-03-17 |
2024-11-01 |
Astrazeneca Ab |
Methods for the purification of bispecific antibodies
|
|
EP4496631A1
(en)
|
2022-03-23 |
2025-01-29 |
F. Hoffmann-La Roche AG |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
IL315526A
(en)
|
2022-03-29 |
2024-11-01 |
Ngm Biopharmaceuticals Inc |
ILT3 and CD3 binding agents and methods of using them
|
|
KR20250004776A
(ko)
|
2022-04-13 |
2025-01-08 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
|
|
JP2025513335A
(ja)
|
2022-04-19 |
2025-04-24 |
エフ． ホフマン－ラ ロシュ アーゲー |
改良された産生細胞
|
|
PE20251172A1
(es)
|
2022-04-26 |
2025-04-23 |
Novartis Ag |
Anticuerpos multiespecificos que se dirigen a il-13 e il-18
|
|
JP2025516631A
(ja)
|
2022-05-12 |
2025-05-30 |
ジェンマブ エー／エス |
併用療法においてｃｄ２７に結合する能力を有する結合剤
|
|
US20250325643A1
(en)
|
2022-05-12 |
2025-10-23 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CN119630690A
(zh)
|
2022-06-03 |
2025-03-14 |
豪夫迈·罗氏有限公司 |
改进的生产细胞
|
|
EP4545564A1
(en)
|
2022-06-23 |
2025-04-30 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereof
|
|
CN119790073A
(zh)
|
2022-06-30 |
2025-04-08 |
詹森生物科技公司 |
使用抗EGFR/抗Met抗体治疗胃癌或食道癌
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
JP2025525885A
(ja)
|
2022-08-05 |
2025-08-07 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
Ｇｕｃｙ２ｃとｃｄ３に特異的に結合する抗原結合分子及びその医薬的使用
|
|
AU2023342086A1
(en)
|
2022-09-15 |
2025-03-13 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
JP2025535744A
(ja)
|
2022-10-12 |
2025-10-28 |
エフ． ホフマン－ラ ロシュ アーゲー |
細胞を分類するための方法
|
|
WO2024089551A1
(en)
|
2022-10-25 |
2024-05-02 |
Janssen Biotech, Inc. |
Msln and cd3 binding agents and methods of use thereof
|
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
CN120051491A
(zh)
|
2022-11-01 |
2025-05-27 |
上海齐鲁制药研究中心有限公司 |
一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用
|
|
AU2023375177A1
(en)
|
2022-11-02 |
2025-06-19 |
Janssen Biotech, Inc. |
Methods of treating cancers
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
CN120187749A
(zh)
|
2022-11-15 |
2025-06-20 |
豪夫迈·罗氏有限公司 |
具有可活化效应结构域的重组结合蛋白
|
|
US20240190978A1
(en)
|
2022-11-15 |
2024-06-13 |
CSBioAsset LLC |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|
|
WO2024104933A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules
|
|
TW202421667A
(zh)
|
2022-11-29 |
2024-06-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Ｃｌｄｎ１８．２／４－１ｂｂ結合蛋白及其醫藥用途
|
|
PE20252169A1
(es)
|
2023-01-20 |
2025-09-04 |
Hoffmann La Roche |
Polipeptidos de dominio fc - variante de il2 recombinantes y politerapia con polipeptidos de union al antigeno anclados a la membrana
|
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
|
TW202436339A
(zh)
|
2023-01-31 |
2024-09-16 |
瑞士商赫孚孟拉羅股份公司 |
治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2024184287A1
(en)
|
2023-03-06 |
2024-09-12 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|
|
WO2024189544A1
(en)
|
2023-03-13 |
2024-09-19 |
Janssen Biotech, Inc. |
Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
|
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
WO2024208776A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
Agonistic split antibodies
|
|
WO2024208777A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
All-in-one agonistic antibodies
|
|
TW202506178A
(zh)
|
2023-04-05 |
2025-02-16 |
丹麥商珍美寶股份有限公司 |
包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
|
|
AR132623A1
(es)
|
2023-05-08 |
2025-07-16 |
Hoffmann La Roche |
PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
|
|
AR132668A1
(es)
|
2023-05-12 |
2025-07-16 |
Genmab As |
Anticuerpos capaces de unirse a ox40, variantes de los mismos y usos de los mismos
|
|
WO2024238537A1
(en)
|
2023-05-16 |
2024-11-21 |
F. Hoffmann-La Roche Ag |
Pd-1 -regulated il-2 immunocytokine and uses thereof
|
|
CA3228195A1
(en)
|
2023-05-23 |
2025-06-30 |
Janssen Biotech Inc |
Methods for treatment of non-small cell lung cancer (nsclc)
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
AR133071A1
(es)
|
2023-06-30 |
2025-08-20 |
Genmab As |
ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4
|
|
US12319747B2
(en)
|
2023-07-03 |
2025-06-03 |
Medicovestor, Inc. |
Methods of using anti-SP17 immunotherapeutics
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
TW202521576A
(zh)
|
2023-07-30 |
2025-06-01 |
美商健生生物科技公司 |
結合至突變型鈣網蛋白之分子及其用途
|
|
WO2025032508A1
(en)
|
2023-08-07 |
2025-02-13 |
Janssen Biotech, Inc. |
Enpp3 and cd3 binding agents and methods of use thereof
|
|
WO2025032510A1
(en)
|
2023-08-07 |
2025-02-13 |
Janssen Biotech, Inc. |
Stabilized cd3 antigen binding agents and methods of use thereof
|
|
TW202523349A
(zh)
|
2023-08-07 |
2025-06-16 |
美商健生生物科技公司 |
Ｇｕｃｙ２ｃ抗體及其用途
|
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
WO2025036892A1
(en)
|
2023-08-14 |
2025-02-20 |
Morphosys Ag |
Cycat halfbody molecules comprising sterically occluding moieties
|
|
WO2025036910A1
(en)
|
2023-08-15 |
2025-02-20 |
Merck Patent Gmbh |
Novel c-met binders and uses thereof
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025052273A1
(en)
|
2023-09-05 |
2025-03-13 |
Janssen Biotech, Inc. |
Methods of treating non-small cell lung cancer
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025079020A1
(en)
|
2023-10-12 |
2025-04-17 |
Janssen Biotech, Inc. |
First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
US12364777B2
(en)
|
2023-10-20 |
2025-07-22 |
Medicovestor, Inc. |
Homodimeric antibodies for use in treating cancers and methods of use
|
|
WO2025114541A1
(en)
|
2023-11-30 |
2025-06-05 |
Genmab A/S |
Antibodies capable of binding to ox40 in combination therapy
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025126102A1
(en)
|
2023-12-12 |
2025-06-19 |
Janssen Biotech, Inc. |
Enpp3 × cd3 bispecific antibodies and use thereof
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
US12116410B1
(en)
|
2023-12-26 |
2024-10-15 |
Medicovestor, Inc. |
Methods of manufacturing dimeric antibodies
|
|
US12121587B1
(en)
|
2023-12-26 |
2024-10-22 |
Medicovestor, Inc. |
Dimeric antibodies
|
|
WO2025153988A1
(en)
|
2024-01-16 |
2025-07-24 |
Janssen Biotech, Inc. |
Use of amivantamab to treat colorectal cancer
|
|
WO2025158277A1
(en)
|
2024-01-22 |
2025-07-31 |
Janssen Biotech, Inc. |
Use of amivantamab to treat head and neck cancer
|
|
US12258396B1
(en)
|
2024-02-02 |
2025-03-25 |
Medicovestor, Inc. |
Methods of using immunotherapeutics that bind folate receptor alpha
|
|
US12378314B1
(en)
|
2024-02-02 |
2025-08-05 |
Medicovestor, Inc. |
Proteins that bind folate receptor alpha including fully-human antibodies
|
|
US12240900B1
(en)
|
2024-02-02 |
2025-03-04 |
Medicovestor, Inc. |
Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025191459A1
(en)
|
2024-03-11 |
2025-09-18 |
Janssen Biotech, Inc. |
Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
WO2025231408A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025233825A1
(en)
|
2024-05-06 |
2025-11-13 |
Janssen Pharmaceutica Nv |
Enrichment of cells expressing a bird linker
|
|
WO2025237931A1
(en)
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|